Development and testing of a decision board to help clinicians present treatment options to lupus nephritis patients in Brazil.

OBJECTIVE Decision boards (DBs) help clinicians present options and include patients in the decision-making process. Our objective was to describe the steps to develop a DB to support shared decision making and assess reliability and construct validity. METHODS Systemic lupus erythematosus (SLE) scenarios were designed with the support of experts for disease severity, potential side effects, and outcomes. The DB comprised clinical information, 2 different treatment options (oral and intravenous), a description of the potential to control SLE within 5 years, and a list of potential side effects. Patients selected what they thought would be the 3 worst side effects and were informed of the probability that these would occur. We presented the DB to 172 patients who were asked to select and justify 1 treatment option. Reliability was assessed by kappa statistics. Construct validity was tested by an a priori hypothesis, analyzing the correlation between treatment decision and side effects selected, self-assessment score, educational level, and clinical aspects. RESULTS Patients favored oral medication, and side effects most often listed were iatrogenic cancer (44.2%), hair loss (21.6%), and severe infection (19.1%). Justifications were risk (48.9%), practicality (36.6%), effectiveness (12.2%), and risk-benefit tradeoff (2.3%). Reliability was similar to that found in the test phase (kappa = 0.689, P < 0.001). Validity was tested by prediction of treatment decision based on the undesirable side effects selected (P = 0.047). DB content was clear and easy for all patients to understand (P = 0.05). Immunosuppressive drugs influenced patient decisions (P = 0.006). CONCLUSION DB is a reliable and valid instrument to assess SLE patient preference.

[1]  M. Pitt,et al.  Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. , 2006, Health technology assessment.

[2]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[3]  Joel W Hay,et al.  Evaluation and review of pharmacoeconomic models , 2004, Expert opinion on pharmacotherapy.

[4]  D. Streiner,et al.  Breast irradiation postlumpectomy: development and evaluation of a decision instrument. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Falk,et al.  Human clinical trials in lupus nephritis. , 2007, Seminars in nephrology.

[6]  D. Gladman,et al.  Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide. , 2007, The Journal of rheumatology.

[7]  T. Sentell,et al.  Literacy and Comprehension of Beck Depression Inventory Response Alternatives , 2003, Community Mental Health Journal.

[8]  E. Faerstein,et al.  [Ethnicity/race in the Pró-Saúde Study: comparative results of two methods of self-classification in Rio de Janeiro, Brazil]. , 2005, Cadernos de saude publica.

[9]  Z. Morad,et al.  Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis , 2005, Nephrology.

[10]  K. Schulman,et al.  Impact of disease severity and gastrointestinal side effects on the health state preferences of patients with osteoarthritis. , 2005, Arthritis and rheumatism.

[11]  D W Baker,et al.  The relationship of patient reading ability to self-reported health and use of health services. , 1997, American journal of public health.

[12]  J. Kirk,et al.  A Randomized Controlled Trial of a Decision Aid for Women at Increased Risk of Ovarian Cancer , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[13]  Amiram Gafni,et al.  Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomized trial. , 2004, JAMA.

[14]  Y. Levy,et al.  Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. , 2004, Arthritis and rheumatism.

[15]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[16]  C. Charles,et al.  Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). , 1997, Social science & medicine.

[17]  S. Danoff-Burg,et al.  Psychosocial research on systemic lupus erythematosus: a literature review , 2004, Lupus.

[18]  G. Contreras,et al.  Maintenance Therapies for Proliferative Lupus Nephritis: Mycophenolate Mofetil, Azathioprine and Intravenous Cyclophosphamide , 2005 .

[19]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[20]  J. Dowie.  The role of patients' meta‐preferences in the design and evaluation of decision support systems , 2002, Health expectations : an international journal of public participation in health care and health policy.

[21]  Mimi Y. Kim,et al.  Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. , 2005, The New England journal of medicine.

[22]  G. Hughes,et al.  Systemic lupus erythematosus , 2001, The Lancet.

[23]  W. Duquet,et al.  The clinimetric qualities of patient-assessed instruments for measuring chronic ankle instability: A systematic review , 2007, BMC musculoskeletal disorders.

[24]  S. Gordon.  Why Does Marxian Exploitation Theory Require a Labor Theory of Value? , 1968, Journal of Political Economy.

[25]  D. Symmons,et al.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. , 1996, Arthritis and rheumatism.

[26]  P. Lipsky,et al.  Positive impact of an intervention by arthritis patient educators on knowledge and satisfaction of patients in a rheumatology practice. , 1999, Arthritis care and research : the official journal of the Arthritis Health Professions Association.

[27]  C. Charles,et al.  Lessons learned from the Decision Board: a unique and evolving decision aid , 2000, Health expectations : an international journal of public participation in health care and health policy.

[28]  M. Dougados,et al.  Feeling good rather than feeling better matters more to patients. , 2006, Arthritis and rheumatism.

[29]  A Gafni,et al.  The physician-patient encounter: the physician as a perfect agent for the patient versus the informed treatment decision-making model. , 1998, Social science & medicine.

[30]  L. Simon,et al.  Patients, their doctors, nonsteroidal anti-inflammatory drugs and the perception of risk , 2006, Arthritis Research & Therapy.

[31]  M. Stewart.  The Medical Outcomes Study 36-item short-form health survey (SF-36). , 2007, The Australian journal of physiotherapy.

[32]  France Légaré,et al.  Risk communication in practice: the contribution of decision aids , 2003, BMJ : British Medical Journal.

[33]  P Adam Kelly,et al.  Integrating validity theory with use of measurement instruments in clinical settings. , 2005, Health services research.

[34]  D. Gladman,et al.  The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[35]  H. Hashimoto,et al.  Patients' preferences for decision making and the feeling of being understood in the medical encounter among patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[36]  G. S. Sahota.  An Economic Analysis of Internal Migration in Brazil , 1968, Journal of Political Economy.

[37]  A. Steinberg,et al.  NIH conference. Lupus nephritis. , 1987, Annals of internal medicine.

[38]  W. Goldsmith,et al.  Cropping systems, structural change and rural-urban migration in Brazil , 1980 .

[39]  C. Gordon,et al.  Quality of life and economic evaluation in SLE clinical trials , 1999, Lupus.

[40]  J. Reveille,et al.  Systemic lupus erythematosus in three ethnic groups. VIII. Predictors of early mortality in the LUMINA cohort , 2001 .

[41]  R. Ciconelli,et al.  Damage index assessment and quality of life in systemic lupus erythematosus patients (with long-term disease) in Northeastern Brazil , 2007, Clinical Rheumatology.

[42]  H. V. van Houwelingen,et al.  Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. , 2007, Arthritis and rheumatism.

[43]  Michael J Barry,et al.  Health Decision Aids To Facilitate Shared Decision Making in Office Practice , 2002, Annals of Internal Medicine.

[44]  C. Mok,et al.  Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups , 2007, Lupus.

[45]  Amiram Gafni,et al.  Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. , 2007, Archives of internal medicine.

[46]  Robert A McNutt,et al.  Shared medical decision making: problems, process, progress. , 2004, JAMA.

[47]  Aileen Clarke,et al.  Developing a quality criteria framework for patient decision aids: online international Delphi consensus process , 2006, BMJ : British Medical Journal.

[48]  D. D'cruz.  Systemic lupus erythematosus , 2006, BMJ : British Medical Journal.

[49]  G. Hughes,et al.  Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. , 2002, Rheumatology.

[50]  E. Balas,et al.  Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success , 2005, BMJ : British Medical Journal.

[51]  A. Gafni,et al.  A Bedside Decision Instrument To Elicit a Patient's Preference Concerning Adjuvant Chemotherapy for Breast Cancer , 1992, Annals of Internal Medicine.

[52]  Gregory T. Smith.  On construct validity: issues of method and measurement. , 2005, Psychological assessment.

[53]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[54]  Nan Cochran,et al.  Help and hope at the bottom of the pile , 2008, BMJ : British Medical Journal.

[55]  C. Charles,et al.  Treatment decision aids: conceptual issues and future directions , 2005, Health expectations : an international journal of public participation in health care and health policy.

[56]  B. Weiss,et al.  Communicating with patients who cannot read. , 1997, The New England journal of medicine.

[57]  Marie Johnston,et al.  Theoretical framework and methodological development of common subjective health outcome measures in osteoarthritis: a critical review , 2007, Health and quality of life outcomes.